GENERAL ADVISE


HOW IS ASSESSMENT OF FAECAL CALPROTECTIN USED TODAY?

  1. Fecal calprotectin testing is widely used as a diagnostic tool to distinguish between inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) . However, it is not a tool for diagnosing IBD alone as elevated calprotectin levels could be attributed to other causes such as colorectal cancer.
  2. There is a strong positive correlation between the disease activity (grade and extent of inflammation) in IBD and the fecal calprotectin level. The test can therefore be successfully used to monitor the effect of treatment.
  3. Fulminant-colitis

    Active-UC
  4. The test is able to identify patients who do not respond to a specific treatment, thereby helping the doctor to make optimal therapeutic decisions. 
  5. When the calprotectin values decrease to a low and persistent stable level below 150 -200 mg/kg a “true” or sustained remission is achieved, and the medication can be adjusted accordingly.
  6. Increasing calprotectin concentrations from the stable level mentioned above indicates relapse which in this way is revealed at an early stage. This is favorable for the patient and his quality of life, making early and appropriate treatment available, thereby shortening the period of fulminant symptoms.
  7. The ability of fecal calprotectin to differentiate between organic and functional disorders makes it a useful and cost effective tool for the clinician, identifying patients with GI symptoms who may or may not require endoscopy or other invasive analyses. Many patients are spared for an uncomfortable examination! This is particularly important in endoscopy of children; general anesthesia is required for this procedure.
  8. Fecal calprotectin is a very convenient marker in the diagnosis of necrotizing enterocolitis in newborn children.
  9. Calprotectin in bile is a promising disease marker in patients with primary sclerosing cholangitis with possible prognostic value.
  10. The diagnosis gastrointestinal graft versus host disease (GI-GVHD), which is a serious complication after allogeneic stem cell transplantation, is based on clinical symptoms and histological findings. No biomarkers are routinely used to predict GVHD. However, recent data demonstrate that elevated fecal calprotectin levels were significantly associated with presence of GI- GVHD, making this marker a promising tool in early diagnosis.

As the original inventor of fecal calprotetin assays the cut off value 50 mg/kg between normal and pathological levels were established by Calpro, based on ground breaking scientific publications. Calpro has kept this critical cut off unchanged since 2000, and this cut off value was confirmed in a study comparing different ELISAs by Labaere. Since 2005 several manufacturers have launched calprotectin ELISAs; each company does their own independent calibration. However, despite values between assays differ considerably and ELISAs from different manufacturers cannot be used interchangeably, they have all adopted 50 mg/kg as cut off.

GOLD-STANDARD

 

CALPRO TEAM

  • Anne Thjømøe

    Executive Chairman 

    Mail: athjomoe@calpro.no

    Direct line: +47 97 73 37 51

  • Inge Dale

    M.D., Ph.D. Chief Medical Officer

    E-mail: idale@calpro.no

    Direct line: +47 91 31 45 03

  • Anne Hancke Framstad

    Laboratory Quality Specialist

    E-mail: aframstad@calpro.no

    Direct line: +47 92 01 14 91

  • Einar Mørk

    Dir. Operations

    E-mail: einar@calpro.no

    Direct line: +47 47 28 55 61

  • Mona Schartum

    Production Manager

    E-Mail: mona.schartum@calpro.no

    Direct line: +47 93 22 73 63

  • Ingvild Haukø

    Sales- and Marketing Manager

    e-mail: ingvild@calpro.no

    Direct line: +47 92 01 52 18

  • Ali Qamar

    Product Manager

    E-mail: ali@calpro.no

    Direct line: +47 41 17 81 19

General Information

Fecal calprotectin in differential diagnosis of irritable bowel syndrome

Li XG, Lv YM, Gu F, Yang XL., Department of Gastroenterology, Peking University Third May 9, 2015

PhiCal Test FDA approved

The PhiCal Test has now been approved by the FDA for clinical use in the USA October 1, 2014

Latest News

Calpro press release regarding MSD agreement

Please see the Calpro press release regarding MDS agreement for delivery of e-health technology CalproSmart:

Norsk | English October 13, 2016

Calprosmart in the Media

Please see our latest articles regarding CalproSmart in Aftenposten and LMF Norge

LMF Norge | Aftenposten October 12, 2016

View all latest